Companies

Sun Pharma inks licensing pact with CSIR-IICT, Hyderabad

Our Bureau Chennai | Updated on August 14, 2019 Published on August 14, 2019

To pay upfront fee of Rs 240 crore for potential development, regulatory and sales milestone

Sun Pharmaceutical Industries on Wednesday said it has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma’s speciality focus areas.

In a release to the stock exchanges, the company said under the agreement, it would get an exclusive global licence for the patents and any other future patents covered in the agreement.

Sun Pharma will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totaling up to Rs 240 crore, plus royalties on net sales from commercialisation of the products developed using these patents.

Sun Pharma will be responsible for development, regulatory filings, manufacturing and commercialisation of these potential products, the statement added.

Dilip Shanghvi, Managing Director, Sun Pharma, said: “This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy to enhance our global speciality pipeline... we are making earnest efforts to bring innovations from Indian research institutes to the market, to address the unmet needs of patients globally. Our collaboration with CSIR-IICT is a step in this direction.”

This agreement will facilitate addition of pre-clinical candidates to Sun Pharma’s global speciality pipeline.

The successful clinical development of these potential compounds may enable Sun Pharma to commercialise pharmaceutical products for various therapeutic indications over the long term.

The stock of Sun Pharmaceutical closed 4.74 per cent lower at Rs 416.80 on the BSE.

Published on August 14, 2019

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.